First Digital Therapeutic App Filed For Approval In Expanding Japan ADHD Market

04 Mar 2024

A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.

Shionogi has been developing the Japanese version of Akili's AKL-T01 since signing the licensing deal in 2019. — Shionogi developing Japanese version of Akili's AKL-T01 since 2019 licensing deal • Source: Shutterstock

Shionogi & Co. Ltd. has filed for the first Japanese approval of a digital therapeutic app, for pediatric attention deficit hyperactivity disorder (ADHD), potentially providing a new treatment option beyond medications in the country's growing market for the disorder.

SDT-001 is a localized Japanese-language version of Akili Interactive Labs’s AKL-T01, which became the first digital app to treat...